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risk patients. METHODS: A decision analysis model compar-
ing the prophylactic administration of palivizumab versus no
administration was built. The analysis included premature
babies 32 gestational age (GA) with/without bronchopulmo-
nary dysplasia, premature babies 35 GA with/without bron-
chopulmonary dysplasia, premature babies 35 GA without
bronchopulmonary dysplasia, premature babies 32–35 GA
without bronchopulmonary dysplasia, and children younger
than 5 years with congenital heart disease. We used the payer
perspective and a temporal horizon of 1 year and the life
expectancy of the babies. The model included administration of
palivizumab (3 doses), hospitalization and death. Efﬁcacy data
came from a systematic review. Direct costs included drug
acquisition and administration, and hospitalization. Determin-
istic univariant sensitivity analyses were performed. RESULTS:
ICER ranged between €17,337.10 and €68,380.77/hospitali-
zation avoided, and between €166,721.18 and €1,476,568.81/
LYG. Considering 5 doses of palivizumab, ICER ranged
between €28,895.16 and €113,967.95/ hospitalization avoided,
and €310,743.34 and €1,073,111.85/LYG. CONCLUSIONS:
The results of the analysis showed that the prophylactic admin-
istration of palivizumab is not efﬁcient preventing hospitaliza-
tions and avoiding deaths. The ICER to prevent one
hospitalization is much higher than the cost of a hospitalization
itself. The ICER per LYG is much higher than commonly
accepted thresholds. These results are consistent with previ-
ously published studies. Differences existed with studies that
included treatment costs of future related diseases, a fact not
supported by current available scientiﬁc evidence.
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OBJECTIVES: Implementation of an HPV vaccine has been pre-
dicted to reduce the burden of cervical cancer. In this research, we
estimated the costs and beneﬁts of the addition of Human Pap-
illoma Virus (HPV) type 16, 18 vaccination to the Dutch cervical
cancer screening program. METHODS: In order to calculate the
cost-effectiveness ratio (ICER) for vaccination Dutch girls against
HPV, we adapted an existing HPV Markov model to The Neth-
erlands. For the base-case analysis, we assumed 100% vaccine
coverage among Dutch 12-year-old girls, a vaccine price of €100
per dose, that no booster vaccination was needed, and cross-
protection against the HPV subtypes 31 and 45 was taken into
account. The model was calibrated according to Dutch incidence
and mortality data. Sensitivity analysis was used to estimate the
robustness and impact of some parameters on cost-effectiveness
ratio. RESULTS: We estimated that the addition of an HPV
vaccine to the Dutch cervical cancer screening program would
cost €31.5 million annually. However implementation of this
vaccination would reduce CIN and cervical cancer costs by €11.5
million and would save 2907 life years (non-discounted). These
ﬁgures give a discounted (4% costs, 1.5% outcomes) ICER of
€22,700 per life year gained (€18,500/QALY). According to
sensitivity analysis, the ICER is sensitive for vaccine price and
discount rate. CONCLUSIONS: Immunization of 12-year-old
Dutch girls against HPV infection is a cost-effective strategy in
protection of these girls against cervical cancer. Although we
made several assumptions, our estimated ICER corresponds with
previous analyses relating to cervical cancer vaccination.
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OBJECTIVES: To assess the cost-effectiveness of mass vaccina-
tion for varicella, based on a dynamic model of varicella and
zoster. METHODS: Priorix-Tetra™ (GlaxoSmithKline Biologi-
cals’ measles, mumps, rubella, and varicella: MMRV) vaccina-
tion is highly protective against measles, mumps, rubella and
varicella and can result in fewer zoster cases in the long term.
Replacing Priorix™ (GlaxoSmithKline Biologicals’ measles,
mumps, rubella; MMR) with Priorix-Tetra™ can sustain a high
vaccine coverage rate for varicella, which might be harder to
achieve with monovalent varicella vaccination. The outcome of
varicella mass vaccination was predicted using a dynamic trans-
mission model. French costs and event rates per varicella and
zoster case (hospitalisation, GP visits, complications and deaths)
were applied. Probabilistic sensitivity analysis was performed.
RESULTS: Mass vaccination decreased varicella incidence from
12,571 to 4,859 per million person-years. After a slight initial
increase, zoster incidence decreased as the vaccinated cohort
aged. The large reduction in varicella and zoster cases with
Priorix Tetra™ resulted in a signiﬁcant number of complications
avoided and more QALYs saved, versus MMR. The direct costs
of vaccination in year 1 were €302,840 with MMRV versus
€207,906 with MMR, due to the higher cost of the tetravalent
vaccine. Signiﬁcant indirect cost savings were achieved compared
with MMR; from €52,043 in year 1 to €1.7 million every year in
the post-vaccination steady-state situation (reached after around
30 years). The cumulative direct cost/QALY saved was €83,000
(year 1, coverage ª20% of MMR replaced), €18,100 (year 5,
coverage ª100% of MMR) and €14,150 (year 30). MMRV was
the dominant cost-effective strategy compared with MMR when
indirect costs were included. CONCLUSIONS: Vaccination with
MMRV provided more QALYs, resulted in fewer complications
and deaths, and reduced direct and indirect costs (excluding
vaccine costs) when compared with vaccination with MMR. The
cost/QALY was €83,000 in year one, dropping to below €20,000/
QALY thereafter.
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OBJECTIVES: The aim of the study is to estimate the cost-
effectiveness of itraconazole in the treatment of invasive
aspergillozis compared to current alternatives (Amphotericin-B,
vorikonazol) using health economic modeling techniques in
Turkish setting. METHODS: Model: In order to evaluate cost-
effectiveness of itraconazole, a decision-tree modelling is used.
The time horizon considered in the model is 12 weeks. The
study is performed from the health care payer perspective.
Patient group: Immunecompromised patients with diagnosis of
invasive aspergillosis. Data sources: The clinical data are
acquired from published clinical studies. Resource use data are
based on expert panel. Prices of medications, institutional dis-
count rates and other costs related to the treatment are
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